<DOC>
	<DOC>NCT00821574</DOC>
	<brief_summary>This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.</brief_summary>
	<brief_title>Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Age between 40 65 years Diagnosed metabolic syndrome Risk of cardiovascular death â‰¥ 5% (according to SCORE) Written informed consent Women not in menopause or not using efficient contraception Known hypersensitivity to study drugs History of ischemic heart disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypertension, dyslipidemia</keyword>
</DOC>